Zobrazeno 1 - 10
of 216
pro vyhledávání: '"J. M. Brotchie"'
Publikováno v:
Parkinsonismrelated disorders. 78
Long-term treatment of Parkinson's disease (PD) with l-DOPA typically leads to development of l-DOPA induced dyskinesia (LID). Amantadine, an NMDA antagonist, attenuates LID, but with limited efficacy and considerable side-effects. NLX-112 (also know
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::452f275a718872e23fd39e30d57664d8
https://pubmed.ncbi.nlm.nih.gov/32846366
https://pubmed.ncbi.nlm.nih.gov/32846366
Autor:
Qi, Li‐Feng‐Rong1 (AUTHOR), Liu, Shuai1,2 (AUTHOR), Fang, Qiuyuan3 (AUTHOR), Qian, Cheng1 (AUTHOR), Peng, Chao4,5 (AUTHOR), Liu, Yuci1 (AUTHOR), Yang, Peng1 (AUTHOR), Wu, Ping4,5 (AUTHOR), Shan, Ling6 (AUTHOR), Cui, Qinghua7 (AUTHOR), Hua, Qian8 (AUTHOR), Yang, Sen9 (AUTHOR), Ye, Cunqi9 (AUTHOR), Yang, Wei2 (AUTHOR) yangwei@zju.edu.cn, Li, Ping1 (AUTHOR) 1019880888@cpu.edu.cn, Xu, Xiaojun1,2 (AUTHOR) xiaojunxu@zju.edu.cn
Publikováno v:
Advanced Science. 10/23/2024, Vol. 11 Issue 39, p1-22. 22p.
Autor:
Cheng, Yan‐Qiong1 (AUTHOR), Zhang, Ruo‐Xi1 (AUTHOR), Li, Xing‐Yuan1 (AUTHOR), Zhou, Xiao‐Ting1 (AUTHOR), Chen, Ming2 (AUTHOR), Liu, Ai‐Jun1 (AUTHOR) mrliuaijun@163.com
Publikováno v:
CNS Neuroscience & Therapeutics. Oct2024, Vol. 30 Issue 10, p1-11. 11p.
Publikováno v:
Neuropharmacology (2006).
info:cnr-pdr/source/autori:J. Lee, V. Di Marzo and J. M. Brotchie/titolo:Role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats/doi:/rivista:Neuropharmacology/anno:2006/pagina_da:/pagina_a:/intervallo_pagine:/volume
info:cnr-pdr/source/autori:J. Lee, V. Di Marzo and J. M. Brotchie/titolo:Role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats/doi:/rivista:Neuropharmacology/anno:2006/pagina_da:/pagina_a:/intervallo_pagine:/volume
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=cnr_________::42b6b24f724d84c8cd37335013f553c4
http://www.cnr.it/prodotto/i/15327
http://www.cnr.it/prodotto/i/15327
Publikováno v:
Drug newsperspectives. 13(5)
Current symptomatic treatments for Parkinson's disease are based largely on dopamine replacement therapies; however, the fact that these treatments are characterized by many long-term side effects has led to widespread interest in nondopaminergic the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0f8563e805ea54b766513f4d36a49ae2
https://pubmed.ncbi.nlm.nih.gov/12937640
https://pubmed.ncbi.nlm.nih.gov/12937640
Publikováno v:
Advances in neurology. 91
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1db1a7658f1406f960e08e688de6a033
https://pubmed.ncbi.nlm.nih.gov/12442686
https://pubmed.ncbi.nlm.nih.gov/12442686
Autor:
S H, Fox, J M, Brotchie
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 15(6)
The involvement of abnormalities in nondopaminergic transmitter systems in Parkinson's disease is noteworthy because of the complications, such as dyskinesia, associated with long-term dopamine replacement therapy. The output regions of the basal gan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9ac4b8f78ef3f206f3a0548d6c1abbba
https://pubmed.ncbi.nlm.nih.gov/11104187
https://pubmed.ncbi.nlm.nih.gov/11104187
Autor:
J M, Brotchie
Publikováno v:
Annals of neurology. 47(4 Suppl 1)
Treatment-related dyskinesias are the major limitation of dopamine replacement therapies such as levodopa in Parkinson's disease (PD). Recent studies in parkinsonian, nonhuman primates have highlighted abnormalities in neural functioning that might u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::02e72bca80d9a51512b96b8f999da8a4
https://pubmed.ncbi.nlm.nih.gov/10762137
https://pubmed.ncbi.nlm.nih.gov/10762137
Autor:
M P, Hill, J M, Brotchie
Publikováno v:
British journal of pharmacology. 128(7)
1. The treatment of Parkinson's disease relies predominantly upon dopamine replacement therapy, usually with l-dihydroxyphenylalanine (L-DOPA). However, side-effects of long-term treatment, such as L-DOPA-induced dyskinesias can be more debilitating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a8dbc53e6eae12f5806f460e90646cee
https://pubmed.ncbi.nlm.nih.gov/10602339
https://pubmed.ncbi.nlm.nih.gov/10602339
Autor:
J M, Brotchie, S H, Fox
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ef04a7e49e49efc4a97dc0e467ca701a
https://pubmed.ncbi.nlm.nih.gov/10493402
https://pubmed.ncbi.nlm.nih.gov/10493402